ChemoCentryx (NASDAQ:CCXI)‘s stock had its “overweight” rating restated by investment analysts at JPMorgan Chase & Co. in a report released on Tuesday. They currently have a $16.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $13.00. JPMorgan Chase & Co.’s price target would suggest a potential upside of 19.58% from the company’s previous close.
Several other equities analysts have also recently issued reports on CCXI. Zacks Investment Research cut ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. BidaskClub raised ChemoCentryx from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. ChemoCentryx presently has an average rating of “Hold” and a consensus target price of $12.13.
ChemoCentryx (NASDAQ CCXI) traded up $0.59 during mid-day trading on Tuesday, reaching $13.38. The company had a trading volume of 159,827 shares, compared to its average volume of 295,676. The company has a market cap of $596.34, a PE ratio of 33.86 and a beta of 1.89. ChemoCentryx has a fifty-two week low of $5.42 and a fifty-two week high of $13.60.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in ChemoCentryx by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock valued at $11,345,000 after buying an additional 13,344 shares during the last quarter. State Street Corp raised its stake in ChemoCentryx by 7.0% during the 2nd quarter. State Street Corp now owns 429,088 shares of the biopharmaceutical company’s stock valued at $4,016,000 after buying an additional 27,896 shares during the last quarter. Northern Trust Corp raised its stake in ChemoCentryx by 9.5% during the 2nd quarter. Northern Trust Corp now owns 276,873 shares of the biopharmaceutical company’s stock valued at $2,592,000 after buying an additional 24,134 shares during the last quarter. Iguana Healthcare Management LLC raised its stake in ChemoCentryx by 10.0% during the 3rd quarter. Iguana Healthcare Management LLC now owns 275,000 shares of the biopharmaceutical company’s stock valued at $2,041,000 after buying an additional 25,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in ChemoCentryx by 21.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 267,066 shares of the biopharmaceutical company’s stock valued at $1,589,000 after buying an additional 46,626 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ChemoCentryx’s (CCXI) Overweight Rating Reiterated at JPMorgan Chase & Co.” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/13/chemocentryx-ccxi-pt-raised-to-16-00-at-jpmorgan-chase-co.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.